Cargando…
Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [(18)F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesion...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501027/ https://www.ncbi.nlm.nih.gov/pubmed/36143386 http://dx.doi.org/10.3390/life12091350 |
_version_ | 1784795369568206848 |
---|---|
author | Skawran, Stephan Messerli, Michael Kotasidis, Fotis Trinckauf, Josephine Weyermann, Corina Kudura, Ken Ferraro, Daniela A. Pitteloud, Janique Treyer, Valerie Maurer, Alexander Huellner, Martin W. Burger, Irene A. |
author_facet | Skawran, Stephan Messerli, Michael Kotasidis, Fotis Trinckauf, Josephine Weyermann, Corina Kudura, Ken Ferraro, Daniela A. Pitteloud, Janique Treyer, Valerie Maurer, Alexander Huellner, Martin W. Burger, Irene A. |
author_sort | Skawran, Stephan |
collection | PubMed |
description | Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [(18)F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesions. Methods: Twenty-four patients were prospectively included to undergo dynamic WB [(18)F]FDG PET/CT for clinically indicated re-/staging of oncological diseases. Parametric maps of Ki and Vd were generated using Patlak analysis alongside SUV images. Maximum parameter values (SUV(max), Ki(max), and Vd(max)) were measured in liver parenchyma and in malignant or inflammatory/infectious lesions. Lesion-to-background ratios (LBRs) were calculated by dividing the measurements by their respective mean in the liver tissue. Results: Seventy-seven clinical target lesions were identified, 60 malignant and 17 inflammatory/infectious. Ki(max) was significantly higher in cancer than in inflammatory/infections lesions (3.0 vs. 2.0, p = 0.002) while LBRs of SUV(max), Ki(max), and Vd(max) did not differ significantly between the etiologies: LBR (SUV(max)) 3.3 vs. 2.9, p = 0.06; LBR (Ki(max)) 5.0 vs. 4.4, p = 0.05, LBR (Vd(max)) 1.1 vs. 1.0, p = 0.18). LBR of inflammatory/infectious and cancer lesions was higher in Ki(max) than in SUV(max) (4.5 vs. 3.2, p < 0.001). LBRs of Ki(max) and SUV(max) showed a strong correlation (Spearman’s rho = 0.83, p < 0.001). Conclusions: Dynamic WB [(18)F]FDG PET/CT is feasible in a clinical setting. LBRs of Ki(max) were higher than SUV(max). Ki(max) was higher in malignant than in inflammatory/infectious lesions but demonstrated a large overlap between the etiologies. |
format | Online Article Text |
id | pubmed-9501027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95010272022-09-24 Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? Skawran, Stephan Messerli, Michael Kotasidis, Fotis Trinckauf, Josephine Weyermann, Corina Kudura, Ken Ferraro, Daniela A. Pitteloud, Janique Treyer, Valerie Maurer, Alexander Huellner, Martin W. Burger, Irene A. Life (Basel) Article Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [(18)F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesions. Methods: Twenty-four patients were prospectively included to undergo dynamic WB [(18)F]FDG PET/CT for clinically indicated re-/staging of oncological diseases. Parametric maps of Ki and Vd were generated using Patlak analysis alongside SUV images. Maximum parameter values (SUV(max), Ki(max), and Vd(max)) were measured in liver parenchyma and in malignant or inflammatory/infectious lesions. Lesion-to-background ratios (LBRs) were calculated by dividing the measurements by their respective mean in the liver tissue. Results: Seventy-seven clinical target lesions were identified, 60 malignant and 17 inflammatory/infectious. Ki(max) was significantly higher in cancer than in inflammatory/infections lesions (3.0 vs. 2.0, p = 0.002) while LBRs of SUV(max), Ki(max), and Vd(max) did not differ significantly between the etiologies: LBR (SUV(max)) 3.3 vs. 2.9, p = 0.06; LBR (Ki(max)) 5.0 vs. 4.4, p = 0.05, LBR (Vd(max)) 1.1 vs. 1.0, p = 0.18). LBR of inflammatory/infectious and cancer lesions was higher in Ki(max) than in SUV(max) (4.5 vs. 3.2, p < 0.001). LBRs of Ki(max) and SUV(max) showed a strong correlation (Spearman’s rho = 0.83, p < 0.001). Conclusions: Dynamic WB [(18)F]FDG PET/CT is feasible in a clinical setting. LBRs of Ki(max) were higher than SUV(max). Ki(max) was higher in malignant than in inflammatory/infectious lesions but demonstrated a large overlap between the etiologies. MDPI 2022-08-30 /pmc/articles/PMC9501027/ /pubmed/36143386 http://dx.doi.org/10.3390/life12091350 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Skawran, Stephan Messerli, Michael Kotasidis, Fotis Trinckauf, Josephine Weyermann, Corina Kudura, Ken Ferraro, Daniela A. Pitteloud, Janique Treyer, Valerie Maurer, Alexander Huellner, Martin W. Burger, Irene A. Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title | Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title_full | Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title_fullStr | Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title_full_unstemmed | Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title_short | Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? |
title_sort | can dynamic whole-body fdg pet imaging differentiate between malignant and inflammatory lesions? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501027/ https://www.ncbi.nlm.nih.gov/pubmed/36143386 http://dx.doi.org/10.3390/life12091350 |
work_keys_str_mv | AT skawranstephan candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT messerlimichael candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT kotasidisfotis candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT trinckaufjosephine candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT weyermanncorina candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT kuduraken candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT ferrarodanielaa candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT pitteloudjanique candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT treyervalerie candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT maureralexander candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT huellnermartinw candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions AT burgerirenea candynamicwholebodyfdgpetimagingdifferentiatebetweenmalignantandinflammatorylesions |